VOLITIONRX LTD (VNRX)
AMEXHealth CareMedical - DevicesSnapshot 2026-11-05
$0.19-6.94%
Close 2026-11-05 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · VNRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -73.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 48.0% |
Growth built into the price is above our model estimate.
The price assumes 121.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 43 industry peers
VNRX — capital allocation
Dated 2026-09-25
Unregistered Sales of Equity Securities Conversions of Note As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC, a Delaware limited liability company (“Lind”), a senior secured convertible promissory note in the original principal amount of $2,400,000. In connection with its obligations under such note, (a) on…
Why it matters: Management called reimbursement the last step before routine clinical use. A delay would keep that path incomplete.
Watch forHospices Civils de Lyon files the reimbursement request. Volition reports approval or a set date for routine clinical use.
Also watch forThe reimbursement request is delayed, denied, or still pending in the next earnings update.
Why it matters: Volition is in talks with more than a dozen firms. A signed deal could bring upfront cash, royalties, or recurring revenue.
Supportive ifVolition announces a signed deal to license or distribute its product. The deal names a partner and gives payment terms or royalties.
Worry ifThe next earnings update reports no signed deal and no partner or payment terms from the talks.
Why it matters: Q2 revenue was flat from a year ago, even as first-half revenue rose. Higher Q3 revenue would show more commercial traction.
Supportive ifQ3 2026 revenue is above $0.4 million and above Q3 2025 revenue.
Worry ifQ3 2026 revenue is $0.4 million or lower, or is below Q3 2025 revenue.
Why it matters: Paying off the note would reduce debt. The latest release said $706,667 remained after a cash payment.
Supportive ifA company release or filing confirms full payment of the remaining $706,667 note balance. It shows no new note conversions.
Worry ifA filing shows the balance remains unpaid after the deferred November and December 2026 payments. Or it shows more share conversion.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$377 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $987 loss on $10,000 · 9.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,807 loss on $10,000 · 98.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.